Curated news about real-world psychedelic research, policy, and developments
LOS ANGELES, CA - May 29, 2026 (NEWMEDIAWIRE) - Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage psychedelic pharmaceutical manufacturer, welcomed final recommendations from Australia’s Therapeutic Goods Administration ...
Updated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's position as the world's leading commercial market for prescribed psilocybin and MDMA VANCOUVER, BC, May 29, 2026 /PRNewswire/ - vi…
Vancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastoge…
Delix Therapeutics presented data for their novel neuroplastogen zalsupindole (DLX-001) at the 2026 American Society of Clinical Neuropharmacology (ASCP) Conference including NeuLogiq® Platform data which supports at-home administration in future trials BELFA…
PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”)…
TAMPA, Fla., May 28, 2026 /PRNewswire/ -- Psilera Inc. ("Psilera"), a leading biopharmaceutical company pioneering next-generation neuroplastogens and psychedelic therapies, today announced the successful closing of an oversubscribed $8.8 million Series Seed …
Most of the psilocybin research that has made headlines over the past decade has carried an implicit qualifier: this is for people for whom nothing else has worked. The participants enrolled in those studies typically had treatment-resistant depression — a co…
Lower-than-approved doses of GLP-1 medications and isotretinoin (Accutane) are trending on social media. Yale Medicine experts discuss safety, effectiveness, and who may—or may not—be appropriate candidates.
DRAPER, Utah, May 27, 2026 /PRNewswire/ -- The FDA recently announced it is shifting regulatory attention and investment for emerging psychedelic-based therapeutics treating mental health conditions. CenExel Clinical Research is answering this push with expan…
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatme…
BALTIMORE, May 26, 2026 /PRNewswire/ -- The Journal of Clinical Psychiatry recently published results from a clinical trial conducted at Sheppard Pratt, examining the efficacy and safety of psilocybin-assisted therapy for individuals experiencing chronic suic…
Inside these vaults lies millions of dollars worth of medicine used in controversial therapies.
Your brain isn't recording reality. It's predicting it. Understanding that one shift explains why psychedelics heal, why therapy matters, and why resistance isn't what we think.
The man behind the Trump administration’s embrace of ibogaine believes that his mission is divine.
What happens when your first psilocybin experience delivers pure joy – Beach Jesus moments, cosmic amplification with a lifelong friend, sun worship by Lake Superior – and then drops you into days of unexplained heaviness? Joel and his integration guide, Just…
Iwamasa - whose hearing is scheduled for May 27 - disagreed with prosecutors' claim that be could have just said 'no' when Perry asked for ketamine.
Management to present corporate update and highlight its next-generation neuroplastogen pipeline TAMPA, Fla., May 22, 2026 /PRNewswire/ -- Psilera, Inc. ("Psilera"), a leading biopharmaceutical company pioneering next-generation psychedelics and neuroplastoge…
Our trial found psilocybin worked fast and lasted months, but unpicking the drug’s true effect from patients’ expectations remains a challenge.
With around three million people in the UK admitting they took illegal drugs in the past year, it's clear that drug-use is becoming ever more normalised.
NEW YORK — Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of…
Félix Schoeller’s team built a realistic artificial-intelligence chatbot to train facilitators needed for research into psychoactive drugs — and, ultimately, to improve public health.
The proposed agreement would grant Jupiter Neurosciences exclusive U. S.
Rhys' hilarious Episode 5 performance is Emmy-worthy.
TORONTO, May 20, 2026 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“PharmAla” or the “Company”), a global leader in the research, development, and manufacturing of novel MDXX-class molecules, today announced that it has entered…
Key opportunities in the esketamine market include addressing the rising prevalence of treatment-resistant depression with rapid-acting esketamine therapies, expanding nasal spray administration for acute psychiatric settings, and enhancing mental health infr…
Health Research Board also reports growing treatment rates for new psychoactive substances and ketamine
The Trump administration has a surprising new agenda item: It’s all-in on legalizing a psychedelic drug called ibogaine. Ibogaine is classified as a Schedule I drug, which means it’s illegal on the federal level. But some studies show it may be able to treat…
PALO ALTO, Calif., May 19, 2026 /PRNewswire/ -- Palo Alto Mind Body, a premier interventional psychiatry practice, today announced the public launch of its Low/No-Cost Interventional Psychiatry Clinic. Designed to eliminate financial barriers to life-saving m…
Analysis showed no photoreactive potential for EB-003, further derisking its continued development for the treatment of neuropsychiatric disorders including depression, anxiety and PTSD. Phototoxicity testing is a part of preclinical safety assessment evaluat…
A single dose of magic mushrooms could help cocaine addicts break the cycle, new research has suggested.
The Amazon contains roughly 80,000 plant species, and ayahuasca requires precisely two of them combined in a way that defies straightforward botanical reasoning — a fact that has puzzled pharmacologists for decades. The post Indigenous Amazonian shamans ident…
Rising global mental health burden and the failure of conventional treatments driving urgent demand for psychedelic medicine. Rising global mental health burden and the failure of conventional treatments driving urgent demand for psychedelic medicine.
Psilocybin showed a signal in a small addiction trial A new clinical trial report finds that a single dose of psilocybin was associated with higher cocaine abstinence than placebo among participants with cocaine use disorder. In the study, people who received…
While the research and support around psychedelic-assisted therapy builds, psychedelic-assisted counselors are meeting the needs of clients in a whole new way.
Imagine walking into a quiet, controlled space where a clinician guides you through a transformative experience—one that could break the cycle of
Trials on veterans suggest the potent hallucinogen could provide a new treatment for PTSD, but scientists still don't know how it works.
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) — Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic ap…
Federal Officials, Researchers, Clinicians and Biopharma Leadership Convened by Psychedelic Medicine Coalition at the National Press Club Vancouver,...
Joshua Bassett is getting candid about his struggle with addiction. The High School Musical: The Musical: The Series alum described his journey to receiving the help he needed after developing an...
The Trump administration is easing restrictions on psychedelic therapies, but the FDA’s slow approval system still stifles innovation.
Learn when to try TMS or ketamine for treatment resistant depression, how neuromodulation therapy works, and what to expect from these advanced depression treatments.
The primary endpoint will measure the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between DT120 Orally Disintegrating Tablet (ODT) 100 µg and placebo Ascend builds on positive Phase 2b study results in general…
NEW YORK — Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced …
Three Phase 3 topline data readouts for DT120 ODT expected in the coming months DT120 ODT program expanded into PTSD with Phase 3 Haven study expected to initiate in 2027 $373.4 million in cash, cash equivalents, and investments as of March 31, 2026, expected…
(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) By Nancy Lapid May 6 (Reuters) - We also report on two more studies involving wildly popular GLP-1 weight-loss drugs, including one...
A single psychedelic trip may cause physical changes in the brain that could explain why some people report psychological benefits from the experience, a small study suggests.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--May 4, 2026-- Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the presentation of data from a randomized, s…
